Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, Carrasquillo MM, et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease. Nat Genet mai. 2011;43(5):429–35.
Dustin ML, Olszowy MW, Holdorf AD, Li J, Bromley S, Desai N, et al. A novel adaptor protein orchestrates receptor patterning and cytoskeletal polarity in T-cell contacts. Cell. 1998;94(5):667–77.
Article PubMed CAS Google Scholar
Kim JM, Wu H, Green G, Winkler CA, Kopp JB, Miner JH, et al. CD2-Associated protein haploinsufficiency is linked to glomerular disease susceptibility. Science. 2003;300(5623):1298–300.
Article PubMed CAS Google Scholar
Gigante M, Pontrelli P, Montemurno E, Roca L, Aucella F, Penza R, et al. CD2AP mutations are associated with sporadic nephrotic syndrome and focal segmental glomerulosclerosis (FSGS). Nephrol Dial Transplant juin. 2009;24(6):1858–64.
Liu YX, Zhang AQ, Luo FM, Sheng Y, Wang CY, Dong Y, et al. Case report: a novel heterozygous mutation of CD2AP in a Chinese family with proteinuria leads to focal segmental glomerulosclerosis. Front Pediatr. 2021;9:687455.
Article PubMed PubMed Central Google Scholar
Takano T, Bareke E, Takeda N, Aoudjit L, Baldwin C, Pisano P, et al. Recessive mutation in CD2AP causes focal segmental glomerulosclerosis in humans and mice. Kidney Int. 2019;95(1):57–61.
Article PubMed CAS Google Scholar
Akilesh S, Koziell A, Shaw AS. Basic science meets clinical medicine: identification of a CD2AP-deficient patient. Kidney Int. 2007;72(10):1181–3.
Article PubMed CAS Google Scholar
Gubler MC. Podocyte differentiation and hereditary proteinuria/nephrotic syndromes. J Am Soc Nephrol. 2003;14(suppl_1):S22.
Shih NY, Li J, Karpitskii V, Nguyen A, Dustin ML, Kanagawa O, et al. Congenital nephrotic syndrome in mice lacking CD2-associated protein. Science. 1999;286(5438):312–5.
Article PubMed CAS Google Scholar
Scheltens P, De Strooper B, Kivipelto M, Holstege H, Chételat G, Teunissen CE, et al. Alzheimer’s disease. Lancet. 2021;397(10284):1577–90.
Article PubMed PubMed Central CAS Google Scholar
2024 Alzheimer’s disease facts and figures. Alzheimers Dement. 2024;20(5):3708‑821.
Rajan KB, Weuve J, Barnes LL, McAninch EA, Wilson RS, Evans DA. Population Estimate of People with Clinical AD and Mild Cognitive Impairment in the United States (2020–2060). Alzheimers Dement déc. 2021;17(12):1966–75.
Golde TE. Alzheimer’s disease – the journey of a healthy brain into organ failure. Mol Neurodegener. 2022;17:18.
Article PubMed PubMed Central CAS Google Scholar
Tremblay C, François A, Delay C, Freland L, Vandal M, Bennett DA, et al. Association of neuropathological markers in the parietal cortex with antemortem cognitive function in persons with mild cognitive impairment and alzheimer disease. J Neuropathol Exp Neurol. 2017;76(2):70–88.
Article PubMed PubMed Central CAS Google Scholar
Han JW, Maillard P, Harvey D, Fletcher E, Martinez O, Johnson DK, et al. Association of vascular brain injury, neurodegeneration, amyloid, and cognitive trajectory. Neurology. 2020;95(19):e2622-34.
Article PubMed PubMed Central CAS Google Scholar
Tremblay C, François A, Delay C, Freland L, Vandal M, Bennett DA, et al. Association of neuropathological markers in the parietal cortex with antemortem cognitive function in persons with mild cognitive impairment and alzheimer disease. J Neuropathol Exp Neurol févr. 2017;76(2):70–88.
Hampel H, Mesulam MM, Cuello AC, Farlow MR, Giacobini E, Grossberg GT, et al. The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease. Brain. 2018;141(7):1917–33.
Article PubMed PubMed Central Google Scholar
Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, et al. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA. 2023;330(6):512–27.
Article PubMed PubMed Central CAS Google Scholar
van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in Early Alzheimer’s Disease. N Engl J Med. 2023;388(1):9–21.
Jucker M, Walker LC. Alzheimer’s disease: From immunotherapy to immunoprevention. Cell. 2023;186(20):4260–70.
Article PubMed PubMed Central CAS Google Scholar
Smith EE, Phillips NA, Feldman HH, Borrie M, Ganesh A, Henri-Bhargava A, et al. Use of lecanemab and donanemab in the Canadian healthcare system: Evidence, challenges, and areas for future research. J Prev Alzheimers Dis. 2025;100068.
Cummings J, Zhou Y, Lee G, Zhong K, Fonseca J, Cheng F. Alzheimer’s disease drug development pipeline: 2024. Alzheimers Dement (N Y). 2024;10(2):e12465.
Mummery CJ, Börjesson-Hanson A, Blackburn DJ, Vijverberg EGB, De Deyn PP, Ducharme S, et al. Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer’s disease: a phase 1b, randomized, placebo-controlled trial. Nat Med. 2023;29(6):1437–47.
Article PubMed PubMed Central CAS Google Scholar
Cummings JL, Osse AML, Kinney JW. Alzheimer’s disease: novel targets and investigational drugs for disease modification. Drugs. 2023;83(15):1387–408.
Article PubMed PubMed Central CAS Google Scholar
Erichsen J, Craft S. Targeting immunometabolic pathways for combination therapy in Alzheimer’s disease. Alzheimers Dement (N Y). 2023;9(4):e12423.
Self WK, Holtzman DM. Emerging diagnostics and therapeutics for Alzheimer disease. Nat Med sept. 2023;29(9):2187–99.
Livingston G, Huntley J, Liu KY, Costafreda SG, Selbæk G, Alladi S, et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. Lancet. 2024;404(10452):572–628.
Bergem AL, Engedal K, Kringlen E. The role of heredity in late-onset Alzheimer disease and vascular dementia A twin study. Arch Gen Psychiatry. 1997;54(3):264–70.
Article PubMed CAS Google Scholar
Gatz M, Reynolds CA, Fratiglioni L, Johansson B, Mortimer JA, Berg S, et al. Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry févr. 2006;63(2):168–74.
Raiha I, Kaprio J, Koskenvuo M, Rajala T, Sourander L. Alzheimer’s disease in Finnish twins. Lancet. 1996;347(9001):573–8.
Article PubMed CAS Google Scholar
Serrano-Pozo A, Das S, Hyman BT. APOE and Alzheimer’s disease: advances in genetics, pathophysiology, and therapeutic approaches. Lancet Neurol. 2021;20(1):68–80.
Article PubMed PubMed Central CAS Google Scholar
Yamazaki Y, Zhao N, Caulfield TR, Liu CC, Bu G. Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. Nat Rev Neurol sept. 2019;15(9):501–18.
Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA. 1997;278(16):1349–56.
Comments (0)